These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 27044549)

  • 21. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D; Critchley IA; Riccobene TA; Thye DA
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
    Saisho Y; Katsube T; White S; Fukase H; Shimada J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A; Isla A; Rodríguez-Gascón A
    Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an
    Werth BJ; Shireman LM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28096164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.
    Monogue ML; Stainton SM; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Bowker KE
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative model-based comparison of target site-specific antimicrobial effects: A case study with ceftaroline and lefamulin.
    van Os W; Pham AD; Eberl S; Minichmayr IK; van Hasselt JGC; Zeitlinger M
    Int J Antimicrob Agents; 2024 May; 63(5):107148. PubMed ID: 38508535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal AnaerobicInfection.
    Wu H; Xie S; Yu J; Chen Y; Wu J; Guo B; Zhu Z; Zhou Y; Wang Z; Zhang J
    Clin Ther; 2018 Sep; 40(9):1548-1555. PubMed ID: 30146271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.
    Bhavnani SM; Hammel JP; Van Wart SA; Rubino CM; Reynolds DK; Forrest A; Drusano GL; Khariton T; Friedland HD; Riccobene TA; Ambrose PG
    Antimicrob Agents Chemother; 2015 Jan; 59(1):372-80. PubMed ID: 25367904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
    Barbour A; Schmidt S; Sabarinath SN; Grant M; Seubert C; Skee D; Murthy B; Derendorf H
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2773-6. PubMed ID: 19364847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis.
    Barsky EE; Pereira LM; Sullivan KJ; Wong A; McAdam AJ; Sawicki GS; Priebe GP; Goobie SM
    J Cyst Fibros; 2018 May; 17(3):e25-e31. PubMed ID: 29103924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A critical review on the clinical pharmacokinetics, pharmacodynamics, and clinical trials of ceftaroline.
    Kiang TK; Wilby KJ; Ensom MH
    Clin Pharmacokinet; 2015 Sep; 54(9):915-31. PubMed ID: 25940827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic Modeling and Probability of Target Attainment of Ceftaroline in Brain and Soft Tissues.
    Helfer VE; Zavascki AP; Zeitlinger M; de Araújo BV; Dalla Costa T
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0074122. PubMed ID: 36005769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
    Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
    Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis.
    Le J; Bradley JS; Hingtgen S; Skochko S; Black N; Jones RN; Lim M; Capparelli EV
    Pediatr Pulmonol; 2017 Nov; 52(11):1424-1434. PubMed ID: 28910514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
    Zhou J; You X; Guo G; Ke M; Xu J; Ye L; Wu W; Huang P; Lin C
    J Clin Pharmacol; 2021 Dec; 61(12):1646-1656. PubMed ID: 34329494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
    Drusano GL
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.